Skip to main content
MedPathMedPath Home
Clinical Trials/CTIS2023-505684-36-00
CTIS2023-505684-36-00
Active, not recruiting
Phase 1

A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)

Janssen - Cilag International0 sites92 target enrollmentAugust 16, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy VolunteersTherapeutic area: Diseases [C] - Immune System Diseases [C20]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Healthy Volunteers
Sponsor
Janssen - Cilag International
Enrollment
92
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 16, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Phase 1
A Study to Evaluate the Safety and Tolerability of Subcutaneous Treprostinil and Pharmacokinetics of a Novel LY900014 Formulation in Healthy Japanese Subjects (I8B-JE-ITRK)Healthy
JPRN-jRCT2080223225Eli Lilly Japan K.K.
Not yet recruiting
Not Applicable
Study to determine the safety and tolerability of combination therapy of TACE (Transarterial-chemoembolization) and Immunotherapy With the Autologous Killer Cell in patients with hepatocellular carcinoma: An open label study
KCT0007346Bundang CHA General Hospital10
Completed
Not Applicable
Safety and tolerability of a vaginal ointment without any active drugs in healthy women.
ACTRN12617000778381Zenith Technology Corporation Limited9
Active, not recruiting
Not Applicable
A study investigating the safety, tolerability and pharmacodynamics of bacterial lipase in patients with cystic fibrosis and pancreatic insufficiencyRandomized, double-blind, placebo-controlled, single period, parallel group desig
EUCTR2006-005180-25-DEordmark Arzneimittel GmbH20
Completed
Not Applicable
A study to investigate the safety, tolerability and absorption and elimination of CCX507-B, a new drug for the treatment of patients with inflammatory bowel diseases, in healthy male and female subjects.Crohn's disease.Inflammatory bowel diseases10017969
NL-OMON40895ChemoCentryx, Inc.30